Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 26;22(9):4501.
doi: 10.3390/ijms22094501.

Biomarkers for Cancer Cachexia: A Mini Review

Zhipeng Cao  1 , Kening Zhao  1   2 , Irvin Jose  1 , Nick J Hoogenraad  1   3 , Laura D Osellame  1   3
Affiliations
Review

Biomarkers for Cancer Cachexia: A Mini Review

Zhipeng Cao et al. Int J Mol Sci. .

Abstract

Cancer cachexia is a common condition in many cancer patients, particularly those with advanced disease. Cancer cachexia patients are generally less tolerant to chemotherapies and radiotherapies, largely limiting their treatment options. While the search for treatments of this condition are ongoing, standards for the efficacy of treatments have yet to be developed. Current diagnostic criteria for cancer cachexia are primarily based on loss of body mass and muscle function. However, these criteria are rather limiting, and in time, when weight loss is noticeable, it may be too late for treatment. Consequently, biomarkers for cancer cachexia would be valuable adjuncts to current diagnostic criteria, and for assessing potential treatments. Using high throughput methods such as "omics approaches", a plethora of potential biomarkers have been identified. This article reviews and summarizes current studies of biomarkers for cancer cachexia.

Keywords: biomarkers; cachexia-inducing factors; cancer cachexia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Sources of cancer cachexia biomarkers. Cancer cachexia biomarkers originate from the host, the tumor, or both. Cachexia inducing biomarkers are shown in black, inflammatory markers in red, muscle and fat wasting products in green, microRNAs in purple, and other factors in grey. MicroRNAs 203 and 130a are not included as the source is unknown.
See this image and copyright information in PMC

References

    1. Aoyagi T., Terracina K.P., Raza A., Matsubara H., Takabe K. Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. 2015;7:17–29. doi: 10.4251/wjgo.v7.i4.17. - DOI - PMC - PubMed
    1. Dunne R.F., Mustian K.M., Garcia J.M., Dale W., Hayward R., Roussel B., Buschmann M.M., Caan B.J., Cole C.L., Fleming F.J., et al. Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia. Curr. Opin. Support. Palliat. Care. 2017;11:278–286. doi: 10.1097/SPC.0000000000000301. - DOI - PMC - PubMed
    1. Crawford J., Johnston M., Hancock M., Small S., Taylor R., Dalton J., Steiner M. Enobosarm, a selective androgen receptor modulator (SARM) increases lean body mass (LBM) in advanced NSCLC patients: Updated results of two pivotal, international phase 3 trials. Support. Care Cancer. 2014;22(Suppl. 1):S30.
    1. Crawford J., Dalton J., Hancock M., Johnston M., Steiner M. Enobosarm, a selective androgen receptor modulator (SARM), increases lean body mass (LBM) in advanced non-small cell lung cancer patients in two pivotal, international Phase 3 trials. J. Cachexia Sarcopenia Muscle. 2014;5:35–78. - PubMed
    1. Laird B.J.A., Balstad T.R., Solheim T.S. Endpoints in clinical trials in cancer cachexia: Where to start? Curr. Opin. Support. Palliat. Care. 2018;12:445–452. doi: 10.1097/SPC.0000000000000387. - DOI - PubMed